Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement

Anticancer Research

Volumn 23, Issue 2 C, 2003, Pages 1757-1762

  Bogdanos, John ^a   Karamanolakis, Dimitrios ^a   Milathianakis, Constantine ^a   Repousis, Panayiotis ^a   Tsintavis, Athanassios ^a   Koutsilieris, Michael ^b,c  

^a METAXA CANCER HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Dept of Experimental Physiology ^*  (Greece)

Author keywords

Anemia; Combined androgen blockade; Prostate cancer; Recombinant human erythropoietin

Indexed keywords

FLUTAMIDE; HEMOGLOBIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT ERYTHROPOIETIN; TESTOSTERONE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY FUNCTION TEST; LABORATORY TEST; LIVER FUNCTION TEST; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ERYTHROPOIETIN, RECOMBINANT; FLUTAMIDE; HEMOGLOBINS; HUMANS; LEUPROLIDE; MALE; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 0037525188     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Labrie F, Dupont A, Subaru R, Cusan L, Gomez JL, Koutsilieris M, Diamond P, Emond J, Lemay M and Candas B: Optimized strategy for the detection of early stage, curable prostate cancer: role of pre-screening with prostate specific antigen. Clin Invest Medicine 16: 425-439, 1993.
2. Labrie F, Dupont A, Cusan L, Gomez LJ, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Tetu B, Emond J and Candas B: Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Medicine 16: 499-503, 1993.
3. 10] LHRH ethylamide in stage C prostatic cancer. Brit J Urology 72: 629-634, 1993.
4. Koutsilieris M, Dupont A, Gomez JL, Cusan L, Suburu R, Diamond P and Labrie F: Stratification of stage D2 prostate cancer patients by a disease aggressiveness score and its use in evaluating disease response and outcome to combination hormonal treatment (GnRH-A plus flutamide). Anticancer Res 14: 627-634, 1994.
5. Dupont A, Gomez JL, Cusan L, Koutsilieris M and Labrie F: Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urology 150: 908-913, 1993.
6. Koutsilieris M, Faure N, Tolis G et al.: Objective clinical response and disease outcome in 59 patients with stage D2 prostate cancer treated with either buserelin or orchidectomy: disease aggressivity and its association with response and outcome. Urology 27: 221-228, 1986.
7. Koutsilieris M and Tolis G: Gonadotropin-releasing hormone agonistic analogs in the treatment of advanced prostatic carcinoma. The Prostate 4: 569-577, 1983.
8. Tolis G, Koutsilieris M, Herrera R, Stellos A, Martinez A and Dufresne M: Advanced prostatic adenocarcinoma: biological aspects and effects of androgen deprivation achieved by castration or agonistic analogs of LHRH. Med Oncol Tumor Pharmacotherapy 1: 129-136, 1984.
9. Byar DP: The Veterans Administration Cooperative Research Group studies of cancer of the prostate. Cancer 32: 1126, 1983.
10. Labrie F, Dupont A, Belanger A et al.: Combination therapy with flutamide and castration (LHRH agonist or orchidectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem 123: 833-41, 1985.
11. Hamilton JB: The role of testosterone secretion as indicated by the effects of castration in man and by studies of pathological conditions and the short lifespan associated with maleness. Resent Prog Horm Res 3: 245-89, 1948.
12. Weber JP, Walsh PC, Peters CA and Spivak JL: Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men. Am J Hemat 36: 190-4, 1991.
13. Eri LM and Tveter KJ: Safety, side-effects and patients acceptance of the luteinizing hormone releasing hormone agonist leuprolide in the treatment of benign prostatic hyperplasia. J Urol 152: 448-52, 1994.
14. Asbell SO and Tester WJ: The incidence of anemia in prostate cancer patients treated with androgen suppression and pelvic radiotherapy. Proc Am Soc Oncol 13: 241, 1994.
15. Strum SB and Tisman G: Anemia of androgen deprivation (AAD) in patients receiving combination hormone blockade: response to erythropoietin. Proc Am Soc Oncol 13: 238, 1994.
16. Chang A, Yeap B, Davis T et al.: Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrole. J Clin Oncol 14: 2250-7, 1996.
17. Modder B, Foley JE and Fischer JW: The in vitro and in vivo effects of testosterone and steroid metabolites on erythroid colony forming cells (CFU-E). J Pharmacol Exp Ther 207: 1004-12, 1978.
18. Leitgeb C, Pecherstorfer M, Fritz E and Ludwig H: Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73: 2535-42, 1994.
19. Henry DH: Recombinant human erythropoietin in the treatment of anemia associated with solid tumors. In: Bauer C, Koch KM, Scigalla, P, Wieczorek L (eds): Molecular Physiology and Clinical Applications. New York: Marcel Dekker, 293-298, 1993.
20. Langer CJ, Choy H and Glaspy JA: Standards of care for anemia management in oncology. Focus on lung carcinoma. Cancer 95: 613-23, 2002.
21. Ganser A: clinical use of erythropoietin in hematology and oncology. In: Overview of the Literature Related to Erythropoietin. 1993. Amsterdam Excerpta Medica 5: 45-51, 1994.
22. Goldenberg SL et al.: Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology 45: 839, 1995.
23. Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M and Smith JA: Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. JAMA 265: 618-21, 1991.
24. Mitsiades C and Koutsilieris M: Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. Expert Opinion on Investigational Drugs 6: 1099-1115, 2001.
25. Sourla A, Lembessis P, Mitsiades C, Dimopoulos T, Skouteris M, Metsinis M, Ntounis A, Ioannidis A, Katsoulis A, Kyragiannis V, Lambou T, Tsintavis A and Koutsilieris M: Conversion of nested reverse-transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients. Anticancer Res 21: 3565-3570, 2001.
26. Koutsilieris M, Mitsiades C, Dimopoulos T, Vacalicos J, Lambou T, Tsintavis A, Milathianakis C, Bogdanos J and Karamanolakis D: Combination therapy of dexamethasone and of a somatostatin analogue in advanced prostate cancer. Expert Opinion on Investigational Drugs 21: 283-293, 2002.
27. Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A and Lambou T: A combination therapy of dexamethasone and somatostatin analog re-introduces objective clinical response to luteinizing-hormone releasing-hormone analog in androgen ablation-refractory prostate cancer. J Clinical Endocrinol Metabol 86: 5729-5736, 2001.
28. Koutsilieris M, Dimopoulos MA, Doillon C, Reyes-Moreno C and Choki I: The molecular concept of prostate cancer. Cancer J 9: 89-94, 1996.
29. Strum SB, McDermed JE, Scholz MC, Johnson H and Tisman G: Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79: 933-41, 1997.
30. Decensi A, Torrisi R and Fontana V: Stimulation of erythropoiesis by the non- steroidal anti-androgen nilutamide in men with prostate cancer. Evidence for an agonist effect; Br J Cancer 69: 617-619, 1994.